National Center for Advancing Translational Sciences logo
NCATS STTR Phase I

NCATS STTR Phase II

Funds U.S. small businesses and their nonprofit research partners to continue and expand translational R&D begun in STTR Phase I toward a commercial product.

OpenNational Center for Advancing Translational SciencesUnited StatesDeep-tech · core fit

NCATS STTR Phase II is the continuation grant that follows a successful STTR Phase I award. It funds the expansion of the R&D work initiated in Phase I, with the goal of producing a commercial product, process, or service. Awards are normally $2,095,748 in total costs over a two-year project period. Applications may exceed this amount with prior approval from the NCATS Grants Management Officer.

Like Phase I, STTR Phase II requires a formal collaboration agreement with a U.S. nonprofit research institution (university, hospital, or federally funded research and development center). The institution must perform at least 30% of the total research effort; the small business must perform at least 40%. The requirement for a nonprofit partner distinguishes STTR from the SBIR program, where no such partner is needed.

Eligible businesses must be U.S.-based for-profit small businesses with 500 or fewer employees including affiliates. A prior STTR Phase I award is required before applying for Phase II — applicants without a Phase I award from the same funding agency (NIH) must provide written justification in what is called a Competing Renewal (Phase IIA). In practice, most applicants hold an active or recently completed Phase I from NCATS or another NIH institute.

Applications are submitted through the NIH SBIR/STTR Omnibus Solicitation, which accepts applications three times per year: January 5, April 5, and September 5. The typical award arrives six to nine months after submission. Applications receive scientific merit review followed by NCATS Advisory Council review before funding decisions are made.

Successful Phase II awardees producing highly promising data may be eligible for a Phase IIB (Competing Renewal) to bridge toward commercialization, but this requires a separate application. NCATS also offers Technical and Business Assistance (TABA) services to Phase II awardees to support commercialization.

Continuation of research and development from STTR Phase I, within NCATS's translational science mission: drug discovery, diagnostics, medical devices, informatics, and platform technologies. NCATS-specific priorities include rare diseases, toxicology, clinical trial innovation, and translational informatics. Phase II must continue work from a prior Phase I — it is not an entry-level grant.

CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.
Next deadlineiThe next date applications are due. Rolling means you can apply any time.5 Sept 2026
Decision timeiTypical time from the deadline to the funder's decision.30 weeks
Project durationiHow long the funded work is expected to run.24 months
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Grant
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.0%
Funding pooliThe total budget available across all awards in this round.—

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see what you submit

Sign up free to see how they score you

Sign up free to see the timeline

Sign up free to see where teams trip up

Last verified: 24 Jun 2026Source: ncats.nih.gov